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Disease Associations
Mark D. Preston and Frank Dudbridge
London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK
Summary
Rare genetic variants are thought to be important components in the causality of many diseases but discovering these
associations is challenging. We demonstrate how best to use family-based designs to improve the power to detect rare
variant disease associations. We show that using genetic data from enriched families (those pedigrees with greater than
one affected member) increases the power and sensitivity of existing case–control rare variant tests. However, we show
that transmission- (or within-family-) based tests do not benefit from this enrichment. This means that, in studies where
a limited amount of genotyping is available, choosing a single case from each of many pedigrees has greater power than
selecting multiple cases from fewer pedigrees. Finally, we show how a pseudo-case–control design allows a greater range
of statistical tests to be applied to family data.
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Introduction
We are interested in the effect on the power of statistical tests
for rare variants when using family-based genetic data. The
main question that we address in this paper is: how best to use
family-based designs to detect rare variant disease associations? To
answer this question, we must investigate two related aspects
of the problem: which designs are most efficient and which
statistical test(s) have the highest power to detect associations.
Our results will enable us to inform future study design and
how best to analyse existing family-based genetic data.
Genome-wide association studies (GWAS) are powerful
tools for locating common genetic variants that affect herita-
ble traits, such as disease susceptibility, but these variants do
not explain the majority of the heritability of most traits. The
remaining heritability is likely to arise from genetic interac-
tions or rare genetic mutations (Maher, 2008; Gibson, 2012)
and it is the detection of rare variants that we are concerned
within this study.
Most GWAS are based on unrelated subjects, particularly
case–control studies in which allele frequencies in the affected
subjects are compared to those in the unaffected. An alter-
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native is to utilise information from the family structure of
the samples and measure the difference in transmission and
nontransmission frequencies of minor alleles to the affected
subjects from their parents (Spielman et al., 1993; Lake et al.,
2000). Family-based analyses have a number of advantages
including controlling for population stratification and offer-
ing allele enrichment (Ott et al., 2011). Between different
strata (or sub-populations) there is the possibility of different
allele frequencies giving rise to false positive disease associ-
ations. Testing the allele transmission controls for this under
the assumption that transmissions of either allele from each
heterozygous single nucleotide variant in both parents are
independent. Furthermore, alleles that increase disease sus-
ceptibility are more prevalent in families that have a history
of affection (Risch & Teng, 1998) and this, in turn, offers
more power to statistical tests through so called enrichment
(Antoniou & Easton, 2003).
Low allele frequencies of rare variants (<1%) cause single
nucleotide polymorphism (SNP) association analyses, such as
those used in GWAS, to be underpowered to detect their ef-
fects (Laird & Lange, 2006). This has led to the development
of rare variant specific tests. These include tests that aggregate
a set of variants into one “super” variant to increase allele
frequency and hence the power of tests to detect associations.
Early examples include the cohort allelic sum (Morgenthaler
& Thilly, 2007) and the combined multivariate and collapsing
(CMC, Li & Leal, 2008) tests. However, collapsing multiple
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variants into one introduces new problems. When the set of
collapsed variants includes nonassociated variants then signal
is weakened through increased noise. If causal variants with
positive and negative associations are pooled together then
they can (partially) cancel each other out, degrading the sig-
nal further. Research has since gone in two directions: how to
improve pool selection (Zhang et al., 2010) and the invention
of tests to overcome these limitations including the sequence
kernel association (SKAT; Wu et al. 2011), kernel-based adap-
tive clustering (KBAC; Lui & Leal, 2010) and C-alpha (Neale
et al., 2011) tests.
These rare variant tests aim for data enrichment through
pooling mechanisms and are not designed for, and therefore
do not take advantage of, the enrichment of rare variants to be
found in families. The problem investigated within is how best
to combine rare variant tests and the enrichment of family-
based data for improving the detection of rare variant disease
association. We will restrict attention to disease affection status
as a binary trait, deferring consideration of quantitative traits
to future work.
Although the potential of family data has been recognised
for some time, there has been relatively little work on adapting
methods for case–control data to family designs. Zhu & Xiong
(2012) presented adaptations of Hotellings T2, the CMC test
of Li & Leal (2008), and two tests based on principal compo-
nent analysis of multiple genotypes, and for dominant models
only, showed improved power compared to case–control de-
signs of comparable size. De et al. (2013) adapted the family
based association tests to combined rare variants, finding sim-
ilar power to comparable case–control studies. Fang et al.
(2012) used between-family information to derive weights
for each rare variant in a combined within-family test. In
contrast to those studies, we take as our point of departure
the best performing multivariate tests for case–control data
(Basu & Pan, 2011) and also consider the relative power of
different family designs. We do not consider the assignment
of weights to each rare variant as this can be treated separately
to the general form of the test statistic chosen.
There are two paths one can choose between when
analysing genetic data from families for rare variant associ-
ation with disease. The first is to utilise pedigree structure
and perform analysis on statistics derived from allelic trans-
missions and pedigree structure. The second is to transform
or replace parts of the family-based data and apply specific
rare variant case–control statistical tests. In this paper we will
investigate both routes.
We begin by describing five new family-based statistical
tests, derived from well-known case–control score tests and
based on the allelic transmissions of the parents to an affected
offspring. We use these tests, with a standard battery of statisti-
cal tests for both rare and common variants. In the alternative
route, we examine two ways to use case–control tests with
the family data. The first method is to create pseudo-controls
from the untransmitted alleles of the parents of each affected
offspring (Cordell et al., 2004) (pseudo-case–control, PCC)
and the second is to retain all of the cases and include new
unrelated controls (unrelated-case–control, UCC).
To determine the characteristics of the proposed tests we
apply them to data simulated in a multitude of different sce-
narios. For each scenario we perform a set of replications to
determine power and error levels of each test. In the Materials
and Methods section we define all of the statistical tests that
are used, including the new family-based tests, the techniques
used to simulate the genetic data and the scenarios that we
use to generate the results. We present our main results for the
rare variant analysis in the Results with additional results to
be found in the Supporting Information. Finally, in the Dis-
cussion section, we put our results on rare variant detection in
context, for consideration in the design of future experiments
as well as the applicability to existing family-based data.
Materials and Methods
In this section, we define the statistical tests and scenarios that
we will use to investigate how best to leverage family-based
genetic data for rare variant disease association analysis. This
includes defining five new score-based tests to take advantage
of family-based genetic data and two transformations that
can be applied to family-based data to create case–control
data. We define a set of simulated scenarios to which we
apply all of these statistical tests in order to elucidate the most
appropriate family-based and/or rare variant analyses to use
under a variety of conditions.
We will assume a known dichotomous (binary) disease sta-
tus and measured genotypes for a set of variants for each
subject. We assume that no data are missing and that the
variants may occur anywhere in the autosomes. We do not
consider covariates although some of the tests have the capa-
bility to include them. The question of disease association we
are answering with respect to these data is:
does having a minor allele at any of the variants confer a
change in an individual’s disease susceptibility?
To answer this question all of the tests employ the same
null hypothesis, namely that none of the SNPs have any effect
on the individual’s susceptibility to the disease. This leads to
the alternative hypothesis that one, or more, of the SNPs
in the group do have an effect on disease susceptibility. The
definition of the alternative hypothesis implicitly includes two
important points: we do not assume a deleterious effect and
we are not testing individual variants for association but the
group as whole. This then puts us in a position to compare
single SNP analyses with multiple test correction with the
grouped analyses used in current rare variant tests.
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New Family-Based Score Tests
We have devised five new family-based score statistics de-
rived from the well-known score statistics. These new
statistics are calculated from the heterozygous parental trans-
mission frequencies to affected offspring, in a similar manner
as the transmission disequilibrium test (TDT). We consider
independent nuclear families consisting of both parents and a
number of full siblings; here we restrict attention to parent-
child trios and parent–sib-pair families. We assume that we
are not working under a prior hypothesis of linkage so that
we may treat transmissions to each sib as independent, and
therefore treat sib-pair families as two independent trios.
We define n to be the number of trios in the data and
m to be the number of variants then we define two n × m
matrices B = {b ij} and C = {c ij} to contain the transmission
information from parents in each each of the trios. From the
ith trio, we let b ij be the count of minor alleles transmitted to
the affected offspring from the parent(s) that are heterozygous
at the jth variant. Similarly, we define c ij as the count of
the major alleles transmitted under the same conditions. Each
value in B and C takes the values 0, 1 or 2. The transmission
disequilibrium found across the trios over all the variants is
measured by B − C.
Combining B and C, we calculate the family-based trans-
mission disequilibrium as X = 12 (B − C). From this, we cal-
culate a family-based score vector U and its covariance matrix
V as
U = XT1 and V = (X − X¯)T(X − X¯),
where X¯ = {x¯ij} with x¯ij = 1n
∑n
k=1 xkj , i.e. each column be-
ing filled with the column average from X.
The first score statistic is the maximum single SNP test,
termed UminP by Pan (2009). The UminP statistic is given
by
TUminP = max
i=1,...,m
u2j
vjj
.
It has an asymptotic null distribution given by a combina-
tion of χ2 distributions (Conneely & Boehkne, 2007) and is
equivalent to testing the significance of the minimum P-value
given by the single SNP association/TDT analysis of the set
of SNPs.
The next three statistics use different estimators of the vari-
ance of UTU . The score statistic is given by
Tscore = UTV−1U
and the sum of squared score (SSU) and weighted sum of
squared score statistics (SSUw; Pan, 2009) are
TSSU = UTU and TSSUw = UTdiag(V)−1U.
The score statistic (Tscore) utilises the full covariance matrix
to generate a statistic that takes account of the (estimated)
linkage disequilibrium structure. The SSU and SSUw are
simplified forms of the score statistic that take into account
less information about the correlation between the variants.
The asymptotic null distribution for Tscore is χ2 with m degrees
of freedom and for TSSU and TSSUw the distributions under
the null hypothesis are combinations of scaled and shifted χ2
distributions (Pan, 2009).
The last test we use that is derived from U and V is the
called the sum test, with statistic
Tsum =
(∑m
i=1 u j
)2∑m
i, j=1 vij
.
This final score statistic assumes that all variants have an effect
on disease susceptibility, moreover that the effect of a minor
allele occurring at each variant is the same, i.e. in the logistic
model βi = β for all i . This has the advantage of reducing
the number of degrees of freedom to one in the χ2 null dis-
tribution and so reduces loss of power through larger degrees
of freedom of the previous tests. Unfortunately it is also very
unlikely to encounter the situation where one has pooled a
set of variants of the same effect size.
The characteristics of these new tests are determined in the
analysis of the Results section and placed into context with
known results about the case–control score tests.
Rare Variant Tests
Rare variants [for our purposes, those with minor allele fre-
quency (MAF) less than 1%] that affect disease susceptibility
are hard to detect with single SNP association tests. These
tests are underpowered unless the sample size is large enough
to provide enough subjects with the minor allele present. To
overcome the low minor allele counts of rare variants a num-
ber of tests have been devised that pool (or collapse) a group
of variants into one “super” variant (Morgenthaler & Thilly,
2007; Li & Leal, 2008). This super variant will have a higher
minor allele count leading to increased power for detection.
However, these collapsing methods introduce their own lim-
itations. Firstly, they only give an indication that at least one
of the group is associated with disease susceptibility. Secondly,
the selection of SNPs to group together may reduce or nullify
the power gained by the increased allele frequency. Power is
reduced through increased noise by including noncausal SNPs
in the group and through cancellation of effects by including
SNPs that have positive associations and SNPs with negative
associations. The next generation of rare variant tests attempt
to address these issues. Three of the most recent and pop-
ular tests are the SKAT test (Wu et al., 2011), kernel-based
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adaptive cluster test (KBAC; Lui & Leal, 2010) and C-alpha
test (Neale et al., 2011).
The C-alpha test utilises the variance of the occurrence
of variants within the group. This allows for both protective
and risk variants, i.e. causal variants with positive and nega-
tive disease association within the group. The test statistic is
given by the normalised sum of observed variances assuming
a binomial model. Explicitly, let
f (a , n) =
(
n
a
)
pa0 (1 − p0)n−a
be the (binomial) probability of seeing a observations in the
cases out of n occurrences in both cases and controls with a
probability p0 of each observation being a case and
v(a , n) = (a − np0)2 − np0(1 − p0)
be its variance. The test statistic is
TC−alpha =
∑m
i=1 v(a i , ni )√∑max(N)
i=2 m (i )
∑i
j=0 v( j, i )2 f ( j, i )
where a i and ni are entries in A and N, respectively, with
m (i ) = ∑nj=0 I (n j = i ) is the number of SNPs with i obser-
vations. The significance is assessed using a one-tailed standard
normal distribution.
The SKAT derives a variance component score statistic
from the logistic regression model as
Tskat = (Y − Y¯1)XWXT(Y − Y¯1)T,
where W is a diagonal weight matrix. Under the null hy-
pothesis, the Tskat statistic follows a mixture of χ2 distribu-
tions. The weights wi , i = 1, ...,m , that lie on the diagonal
of W, are chosen to place more or less emphasis in the anal-
ysis on each of the m variants. It is recommended, in rare
variant analysis, to define the weights from a beta distribution
by
√
wi = Beta(MAFi , a1, a2) with 0 < a1 ≤ 1 and 1 ≤ a2
where MAFi , i = 1, . . . ,m are the observed MAFs at each
variant. Wu et al. (2011) use a1 = 1 and a2 = 25 that places
greater emphasis on the rare variants and less on common
variants. Taking a1 = a2 = 1 is a special case that is asymp-
totically equivalent to the C-alpha and SSU tests.
The final rare variant test that we examine is the KBAC
test. This test performs a joint comparison of the frequencies
of the genotypes that appear in the genetic data between the
cases and controls. The first step is to count the number of
occurrences of each genotype in the cases and controls. The
genotype for each subject is represented by a row in X. Let the
null genotype be a lengthm row vector of 0s. This equates to a
subject having two copies of the major allele at every variant.
Let us assume that there are k different nonnull genotypes
in our data X. We let n Ai , i = 1, ..., k be the counts of each
genotype in the cases and nUi be the counts of each genotype
in the controls. The KBAC statistic is
TKBAC =
(
k∑
i=1
(
n Ai
n A
− n
U
i
nU
)
k
(
n Ai , n
A
i + nUi , n A, n
))
,
where n A = nY¯ is the total number of affected cases, nU =
n(1 − Y¯) is the total number of unaffected controls and the
kernel function k is chosen to assign weights according to the
size of the data. For small data an hyper-geometric kernel is
most appropriate with
k
(
n Ai , ni , n
A, n
) =
(ni
n Ai
)( n−ni
n A−n Ai
)
( n
n A
)
An alternative for small n is the marginal binomial kernel
and for large n is the asymptotic normal kernel (Lui & Leal,
2010). As asymptotic distributions of the statistic under the
null are not available P-values are obtained empirically via
permutation procedures.
It is worth noting that, although not derived as such, the
KBAC statistic amounts to a signed difference in genotype
frequencies between cases and controls, and is greatest when
genotypes are common in cases and rare in controls. There-
fore, it is expected to be most powerful when variants are rare
in the general population and have effects in the direction of
risk, and this has been borne out by simulation studies (Lui
& Leal, 2010; Basu & Pan, 2011).
Family Data and Transformations
Family data in genotyping studies come in many different
forms, from parent–child trios to extended pedigrees with
many affected relatives. There may even be mixtures of many
different pedigree structures. In this study, we choose three
basic family structures to demonstrate the key properties of
the rare variant association tests.
The first is the parent–child trio, composed of two parents
of unknown affection status and a single affected offspring.
This is the most common unit of a family-based study design.
The second is an affected sib-pair (ASP), consisting of two
affected full siblings and their two parents. There, any causal
alleles will be enriched over those found in a trio (Risch
& Teng, 1998). This structure may cause independence is-
sues due to the nonindependence of genetic information in
related cases. An ASP is decomposable into two trios, with
the parents appearing in both. The last family structure we
term an enriched trio. We use only one trio from an ASP,
i.e. we ignore one of the affected siblings. Any causal alleles
will be enriched as in an ASP (Risch & Teng, 1998) and
there are no independence issues to contend with. We re-
gard this structure as an example of a family-based design in
which cases are selected for a family history of disease. Similar
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designs in the case–control setting have been shown to offer
improved power (Antoniou & Easton, 2003; Dudbridge et al.,
2012).
Throughout we assume that we have family-based genetic
data to begin with. We now describe two ways to transform
family-based data into case–control format, to which existing
case–control statistical tests may be applied. The data resulting
from these transformations are called PCC and UCC. The
advantage of having case–control data is that a wider range
of tests are available, specifically in the section named Rare
Variant Tests.
In the first of these transformations, we utilise the trans-
mission information in each trio to create controls. In each
trio a new pseudo-subject, created from the untransmitted
alleles of the parents, is taken to be a control. Combining
these pseudo-controls with the affected offspring (the cases)
creates a data set containing an equal number of cases
and controls. We create only one of the three possible
pseudo-controls per trio, which is the one based on the two
untransmitted alleles, as this corresponds to the unmatched
case–control design assumed by the tests we consider (Cordell
et al., 2004). The second transformation uses the affected
offspring as cases, and samples unrelated controls from the
population. Combining these unrelated controls with the
cases creates the UCC data set. The question of how these
controls are gathered will be addressed in the Discussion
section. We apply these two transformations in turn to the
same initial family-based data. This reuse of the cases for
PCC/UCC formats (and parental data for PCC format) has
the effect of mimicking the choices available to real-world
data.
In both transformations the new case–control data sets may
violate independence assumptions in the derivations of the
statistical tests. We address this, when it occurs, by applying
a clustering algorithm. In the scenarios defined below with
families containing multiple affected offspring then the af-
fected offspring contribute multiple cases to the PCC and
UCC data sets. These cases are not independent. For ex-
ample, two affected siblings are expected to share at least
50% of their genetic make-up. This dependence can lead to
underpowered tests or inflated type I error rates. The clus-
tering algorithm we apply sums the count of minor alleles
at each variant in related cases to create one case and the
same for their matched controls. This reduces the number
of cases and controls by a factor equal to the cases in each
pedigree (a factor of 2 for ASPs) but maintains independence
of the new samples enabling the case–control tests to be ap-
plied successfully. Of course this will affect the power, as
we will see in the Results section. This approach is equiva-
lent to calculating U and V in the New Family-Based Score
Tests section using families as the sampling unit rather than
individuals.
Scenarios
To assess the performance of the various combinations of
family structures, data transformations and statistical tests we
perform a simulation study. We use simulated data, the trans-
formed data and familial relationships as inputs to each of the
statistical tests defined above. We repeat these simulation and
statistics steps 1000 times. The power and type I error for
each statistical test is determined by the proportion of times
that the statistic reports an association at P < 5%.
The overall process is given by the flowchart in Figure S3.
When simulating subjects we must determine their affection
status. To do this, we employ a logistic model. In the logistic
model the chance of being affected by the disease for any
given genotype is determined from the following equations:
P (D|G) = 1
1 + exp(−γ ) , γ = ln
(
c
1 − c
)
+
m∑
i=1
ln(ORi )g i , (1)
where p (D|G) is the probability of a subject being affected
with the disease given the subject multi-variant genotype of
G, c is a background chance of being affected for a subject
with no minor alleles, ORi is the effect size of variant i
and g i is the number of minor alleles at the ith variant. The
background chance of being affected with a disease represents
the probability of affection from unmeasured factors such as
other causal SNPs and environmental factors.
Firstly the six family-based tests (the single SNP TDT and
the five new family-based score tests) are applied to the origi-
nal family data. Next, the nine case–control tests (single SNP
association, five score tests, SKAT, KBAC and C-alpha) are
applied to the PCC format genetic data. Finally, the same nine
tests are applied to the UCC data. These tests are summarised
in Table S1. The nonindependence of cases when derived
from ASP data, as discussed above (in the Family Data and
Transformations section), led to four tests being inappropriate
in the UCC setting for ASP derived data. The type I error
rates results are presented in the Results section. For the score
tests on UCC/ASP data clustering was used. In addition, the
asymptotics of the C-alpha test failed due to the low MAF so
permutation testing was used and this test is denoted Cα-P.
The parameter space for the simulations includes the famil-
ial structure, the number of variants, the MAF at each variant
and the number and effect size of any causal variants. To fully
explore this parameter space we take a systematic approach to
the choices of these simulation parameters. We firstly see how
each test performs under the null scenario of no association
with all OR equal to 1 for each familial structure. Next, we
define three baseline scenarios that provide a starting point
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for our analysis into the trio, ASP and enriched trio family
structures.
The baseline scenarios all contain 10 variants with MAF of
0.5% and a baseline prevalence of 1% [c = 0.01 in the logistic
model, Eq. (1)], see Table S2. Four of these variants are causal
variants, i.e. any minor alleles occurring at any of these four
variants confer increase in the chance of being affected by the
disease. We choose the OR to be equal for each of the four
causal variants and to be set at a level that causes the most
powerful test to have a power of approximately 90%. This last
condition ensures that we are receiving a clear signal in the
sense that were the OR too high then many tests may give
(or close to) 100% power or if the OR were too low then
the signal would be indistinguishable from the false positives.
The OR for trios, ASPs and enriched trios in their baseline
scenarios are 2.00, 1.72 and 1.54 that give disease prevalences
of 1.21%, 1.15% and 1.11%, respectively.
We then examine perturbations from these baseline param-
eters. In the first set of scenarios we change the number of
causal variants from one to ten. We alter the OR at the same
time to maintain approximately 90% power for the most pow-
erful test. This set of scenarios alters the proportion of causal
variants within a fixed total number of variants. The next set
of scenarios alters the proportion of causal variants by keep-
ing the baseline four causal variants and increasing the total
number of variants. For the following two sets of scenarios
we fix the number of causal variants at one and four, out of
ten, and vary the effect size with the OR ranging from 1.0 to
3.0. The fifth and sixth sets of perturbations on the simula-
tion parameters examine the effects of having nonequal OR
causal effect sizes. In the fifth, we include protective variants
and in the sixth we fluctuate the OR by up to ±20%. In the
seventh, we investigate population stratification by simulating
cases from two populations with MAF and OR given in Ta-
ble S2. Finally, we examine the effect of reducing the sample
size. In all the previous scenarios, we have kept the number
of cases at 1200; in this set of scenarios we test subsets of size
100 to 1100 for changes in power.
To perform the simulations we use the dwarf tool (Preston,
2013). This tool combines a powerful simulator with the abil-
ity to call R scripts (Ihaka & Gentleman, 1996) and run inbuilt
statistical tests. The variants are independently simulated and,
as in (Basu & Pan, 2011; Pan, 2009) and others, the conclu-
sions are robust to linkage disequilibrium structure.
Results
We begin by presenting the type I error rates for each statistical
test with the null simulation parameters using a significance
level of 5% (see Table 1).
With only one exception for a Cα-P test, the trio and
enriched trio false positive rates are all within a strict bound
(≤5.5%) and relaxing this bound does not alter the con-
clusions below. The single SNP tests (TDT, association and
UminP) are shown to be consistently conservative (≤4%). We
found the analytic P-value calculation for the C-alpha test to
be inaccurate due to the low MAFs encountered in these
simulations, hence our use of the permutation method when
testing this statistic to correct this problem. The tests on ASP
family data are more interesting. All error rates for the UCC
data derived from the ASP family data are over 8% deeming
them all inappropriate for general use. By using the clustering
algorithm on the score tests (see the section named Family
Data and Transformations) their type I error rates drop to
those presented in Table 1. Three of these error rates are still
high but the SSU and sum tests are acceptable.
Recall that the baseline scenario consisted of 10 variants
with MAF of 0.5% and four causal variants of equal OR
dependent on the pedigree structure (2.0 for trios, 1.72 for
ASPs and 1.54 for enriched trios). The power estimates for
these scenarios are given in Table 2.
The family-based statistical tests and the PCC statistical
tests give very closely the same power for every test in each
of the family structures (comparing columns 1 and 2, 4 and
5, 7 and 8, Table 2). Furthermore, so do the statistical tests on
UCC data derived from trios with the other statistical tests for
trios (comparing columns 1, 2 and 3). For the UCC statistical
tests we see an increase in power over the equivalent family
and PCC tests for tests on ASP (column 6) and enriched trios
data (column 9). The increase for ASP data is tempered by
the high type I errors seen above.
The table is split into groups. These divide the statistical
tests into groups that are theoretically closely related and/or
have a large correlation in their power. These relationships are
maintained throughout the analyses. Figure S4 demonstrates
this for these five groups over the first three sets of scenarios:
changing number of causal variants and increasing OR for
one and four causal variants. In the right-hand two columns
of panels in Figure S4 (for ASP and enriched trio results)
we see confirmation of the extra power of UCC tests. We
also see a consistent but small reduction in power for the
SKAT test compared to the SSU and Cα-P. As the SKAT is
a parametrisation/generalisation of these other two tests we
conclude that it is the parameters that may need adjusting.
Any adjustment may improve the SKAT performance but not
by any significant amount to warrant differing conclusions
throughout our work.
We use these relationships to clarify the presentation of
our results in the subsequent scenarios. From each group and
family structure combination we will select one statistic with
one data format to be indicative of them all. This gives five
statistics to consider for each of the family structures and 15
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Table 1 The false positive (type I) error rates (in %) for all statistical tests for each family structure (trios, ASPs and enriched trios). Within
each family structure there are 24 statistical tests over the three data formats (family, PCC and UCC). Those in bold indicate an error rate of
over 5.5%.
Trios ASPs Enriched Trios
Fam PCC UCC Fam PCC UCC Fam PCC UCC
TDT 3.6 – – 4.9 – – 3.8 – –
Assoc. – 3.6 4.8 – 4.8 11.0 3.7 3.9
UminP 3.6 3.8 5.0 5.0 4.8 6.0 3.8 3.8 4.4
SSU 4.0 4.1 5.4 5.0 4.9 4.6 5.3 5.3 4.9
Cα-P – 4.6 5.8 – 5.6 16.0 – 5.5 5.5
SKAT – 4.2 5.2 – 4.9 14.8 – 5.4 5.3
SSUw 4.6 4.5 5.1 5.2 5.1 6.1 4.8 4.9 5.4
Score 4.9 4.7 5.1 5.4 5.0 6.1 5.5 4.9 5.1
Sum 4.4 4.6 4.6 6.4 6.2 5.0 4.3 4.3 5.0
KBAC – 5.5 5.2 – 5.4 9.8 – 4.7 4.7
Table 2 All power results (in %) for the baseline scenarios. The optimal results for three family structures are given in bold and dashes
represent tests that failed to maintain a low type I error or are not applicable for that data set. The results are grouped according to
correlations between statistical tests, see main text for further details.
Trios ASPs Enriched trios
Fam PCC UCC Fam PCC UCC Fam PCC UCC
TDT 57 – – 44 – – 24 – –
Assoc – 57 57 – 44 – – 24 53
UminP 56 58 58 43 45 58 24 24 53
SSU 83 84 85 73 74 91 45 45 79
Cα-P – 84 85 – 75 – – 46 80
SKAT – 83 84 – 72 – – 43 78
SSUw 75 76 78 62 63 82 35 35 73
Score 76 76 78 63 63 81 36 35 72
Sum 78 78 78 72 71 86 45 45 76
KBAC – 91 91 – 85 – – 62 89
in total. As there is no significant difference between any of
the statistics used in each box for the trio data we select the
UminP, SSU, score, sum and KBAC tests with UCC data. This
enables our results to be directly compared to those in other
work. For enriched trios we make the same selections. The
tests on UCC data have a large increase in power throughout.
The results for ASP derived data are not so clear cut. The
increase in power when using UCC data is, as for the enriched
trios, pronounced but this is at the expense of potentially
higher type I errors. We make the same choices as for the trio
and enriched trio settings with UminP, SSU, score and sum
tests with UCC data and use the KBAC test with PCC as
well. The SSUw and score tests that have high type I errors
do not perform as well as the SSU and sum tests that have
acceptable type I errors. At no point in the analyses below do
tests with type I error greater than 5.5% perform optimally.
Figure 1A presents the relative power of each statistical test
as the number of causal variants increases from 1 to 10. The
SSU test performs well at low numbers of causal variants. As
the proportion of causal variants increase then the KBAC and
sum tests come to the fore. The KBAC test is best for trio
and enriched trio data at higher numbers of causal variants. It
does not perform as well as the sum test for ASP data.
In the second and third set of scenarios, Figures 1B and
S1A, we fix the number of causal variants at one and four,
respectively, and vary the effect size (OR). The extra sensi-
tivity to low effect sizes in enriched families is clearly evident
comparing results for trio data (left panel) to the other results.
For a single causal variant the SSU group of tests outperform
all other tests including, surprisingly, the single SNP tests with
multiple test correction. When there are multiple causal vari-
ants the KBAC test has a power increase over the other tests
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Figure 1 Results for three simulated scenarios. The power is presented in each case with
the results for trio derived data on the left, ASP derived data in the middle and enriched
trios on the right. (A) The number of causal variants increases from 1 to 10 and the OR is
varied to maintain an approximate 90% highest absolute power. (B) For four causal variants
we jointly vary their ORs from 1 to 2. (C) While keeping four causal variants we change
the direction of the effect of an increasing number of them, from four causal and no
protective variants (the baseline scenatio, left) to four protective and no casual variants
(right).
for trio and enriched trio data. The sum and SSU tests are
optimal for ASP data and most noticeably the KBAC loses
power.
In these results, the SSU test shows optimal power through-
out unless the proportion of causal variants is over 20%. The
KBAC test demonstrates greater power when the number of
causal variants rises above this level but is penalised in the ASP
tests. This lack of power has two potential sources: the lack of
independence in the cases and the lack of relative genotypic
variation found with pseudo-controls.
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As we increase the total number of variants in our data,
keeping only four causal, we observe in Figure S1B a similar
result to Figure 1A. As the proportion of causal variants drops
below 20% the SSU test outperforms the KBAC test in trio
and enriched trio data. In Figure 1C, where we have replaced
an increasing number of the four causal variants with protec-
tive ones of equal but opposite protective effect size, the SSU
test outperforms the KBAC again. This is to be expected as
the SSU is a variance based test, i.e. only the effect deviation
contributes irrespective of direction. The sum test, that per-
forms noticably worse, and the KBAC test are not designed
to take these variants into account and this reduces the power
when they are present.
The fluctuation tests involving perturbations of the effect
sizes showed no deviation from the main results and are omit-
ted.
In Table S3 the type I error rates for a stratified population
lead to the same conclusions as the baseline tests (c.f. Table
1), namely that the error rates for UCC data derived from the
ASP families are too high and that the single SNP tests are
consistently conservative. We again employed the permuta-
tion method for the C-alpha test and clustering for the score
tests for P-value calculations. The stratified populations, that
are stratified by MAF, OR and baseline prevalence, give the
same optimal tests as the baseline scenarios. For all family data
using an UCC format is best, with the KBAC test optimal for
independent cases (trios and enriched trios) and the SSU test
for ASP family data.
An important consideration when choosing appropriate
study designs and statistical tests to apply is the amount of
data available. In Figure S1C, the power of each statistical test
is presented for a subset of the 1000 cases used in each of the
baseline scenarios. The power drops off almost linearly in each
case. The order of tests by performance in the main results
holds, with the exceptions that the sum test outperforms the
SSU test at less than 500 cases and the KBAC test for ASP
PCC data overtakes both the SSU and sum tests.
In Figure 2 we present our key result. This figure presents
the relative power of the five score tests for family (left), PCC
(middle) and UCC (right). While keeping all other parameters
equal (MAFs, ORs, number of causal variants, etc.) the results
for simulations derived from 600 ASPs (blue, 1200 cases),
300 ASPs (red, 600 cases), 600 enriched trios (magenta, 600
cases) and 900 trios (black, 900 cases) are displayed. This
demonstrates the amount of information in the cases relative
to the different test types (transmission or frequency) and
different control types (pseudo or unrelated). We clearly see
that 600 enhanced cases (from ASPs or enriched trios) are
the equivalent of 900 normal cases (from trios) for statistical
tests on family-based and PCC data. When unrelated controls
are introduced, the results for 600 ASPs and 900 trios remain
(albeit with greater variation) at about half of the power of
the 1200 ASPs results. For the same number of cases (600),
the increase in power in the results for 600 enriched trios data
over the results for 300 ASPs data is clear.
Discussion
Family-based designs have had appeal for detecting associa-
tion of rare variants because such variants are more common
within families with multiple affected subjects. Here, we have
compared some basic but key types of family-based design
to case–control studies with the same number of cases, us-
ing a range of current methods for detecting rare variants.
We demonstrate unequivocally that combining cases from
enriched families with unrelated controls gives the greatest
power to detect rare variants. In particular, when cases with a
family history are used, it is more powerful to study these cases
in a case–control rather than a case–parent trio or ASP de-
sign. In contrast, when unselected cases are used there are no
differences in power between family-based and case–control
designs.
Figure 2 illustrates this most clearly. In the left two panels
600 cases from ASPs (300 families), 600 cases from enriched
trios (600 families) and 900 cases from trios (900 families) are
clearly equally powered for both family and PCC statistical
tests. When unrelated controls are introduced there is a sig-
nificant increase in power for the statistical tests when applied
to enriched trios. As enriched trios are a typical example of
a strong family history of affection we conclude that, for a
fixed number of cases, taking one case per pedigree and hav-
ing more pedigrees is a more powerful design than taking
multiple affected individuals from fewer pedigrees.
It may seem surprising that the case–control design has
a significant increase in power over the family-based design
when the cases have a family history, but not otherwise. The
reason is that, under multiplex ascertainment, pseudo-controls
constructed from untransmitted haplotypes are not typical
of the general population (Thomson, 1995; Cordell, 2004).
Therefore the parallel between family-based designs and case–
control studies no longer holds, and we have shown that the
case–control design is more powerful. While this result holds
for both common and rare variants, the presence of a family
history is particularly relevant for studies of rare variation as
their effects are more likely to be strong and thus to account
for that history (Maher, 2008).
Transmission statistics calculated though specific family-
based formulae or by using pseudo-controls with case–control
methods are shown to have equivalent power. As there are
many well-researched and designed case–control statistics to
test for rare variant disease associations, the PCC data format
provides a larger set of tests to apply than for the original
family-based format. For example, while we could easily adapt
the SSU (Basu & Pan, 2011) to transmission statistics, the
KBAC (Lui & Leal, 2010) is more easily applied to cases and
pseudo-controls.
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Figure 2 We show the relative power of each of the five score tests to the power of the score tests from data derived from 600 ASPs
(1200 cases, black). Results are presented from data derived from 300 ASPs (600 cases, blue), 600 enriched trios (600 cases, green)
and 900 trios (900 cases, red). The family-based tests are on the left, the pseudo-case–controls in the middle and
unrelated-case–controls on the right.
When it comes to selecting the most appropriate statistical
test then two groups of tests stand out. The SSU group (in-
cluding SKAT and C-alpha) and KBAC statistics consistently
perform the strongest over the battery of scenarios applied.
The equivalencies seen in our results and in analytical work
(Basu & Pan, 2011; Wu et al., 2011), and the subsequent
groupings we defined (Tables 1 and 2; Fig. S4), conform
with expected relationships (e.g. the single SNP tests: TDT,
association and UminP are equivalent).
The KBAC test performs the best when there is a high
proportion of causal variants (see Figs 1A, B and S1B). Its
superiority is clear with 40% causal variants (see Fig. 1B).
Its suboptimal performance with only one causal variant is
shown in Figure S1A. The KBAC test also shows greater
relative power at low sample numbers, albeit with an absolute
power of less than 50% (see Fig. S1D).
The central unknown of real-world data analysis is the
causality of any variant. Therefore, with large GWAS-type
studies, is it realistic to expect over 20% of rare variants in a
pool to be measureably causal? If the answer to this question
is yes then the KBAC test is most suitable. In most studies this
assumption cannot be made and the SSU group of statistical
tests comes to the fore.
The SSU group consists of the SSU, SKAT and C-alpha
tests. These are variance based statistics that perform the best
up to 40% causal variants (see Fig. 1A) and especially at low
proportions (see Fig. S1E). They incorporate protective vari-
ants (unlike KBAC; Fig. 1C) and maintain strong relative per-
formance at low sample sizes (see Fig. S1F). They also (with
clustering) perform the strongest when multiple affected in-
dividuals from one pedigree are included in the data set. The
SKAT can be considered a generalisation of the other two
tests via its parameterisation. The recommended parameters
for rare variant testing with SKAT did not outperform the
basic tests in our scenarios, so may require further investiga-
tion.
Our results with a single causal variant are noteworthy (see
Figs S1A and S4). We show the equivalence of TDT, associ-
ation and UminP statistics for trios and UCC. These contra-
dict the assertions of Laird & Lange (Laird & Lange, 2006),
who claimed that trios have greater power than case–controls
for low penetrance diseases with rare variants, in contrast
to analytic results (Risch & Teng, 1998). Furthermore, we
show that the SSU group of tests outperform the single SNP
tests with multiple test correction when there is only a sin-
gle causal variant. This result, which is surprising, does not
apply to common variants, and further motivates the use of
multivariate statistics such as SSU and SKAT with rare variant
data.
In the baseline scenario (Table 2) and the scenarios with
varying numbers of causal variants we manipulated the effect
size of the causal variants to maintain the optimal power at ap-
proximately 90%. The effect sizes used are presented in Figure
S2. The required OR to give this optimal power obviously
reduces as the number of causal variants increases. The effect
size is also much smaller for enriched trios than ASPs and
for ASPs than trios. This indicates the greater sensitivity of
tests applied to enriched family data. The jump from trios to
enriched families (ASPs and enriched trios) can be attributed
in large part to the increase in MAF of causal variants in the
cases. Cases in ASPs and enriched trios have the same MAF
for causal variants but enriched trios show a greater sensi-
tivity. This is due to the increase in power due to the inde-
pendence of samples. In the ASP and larger pedigree settings
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nonindependence and the use of a clustering algorithm in-
hibits power and therefore sensitivity.
We have presented results that indicate future studies should
use unrelated controls with cases but what is the implication
for existing family-based data? We have shown that when cases
are selected from families with multiple affected individuals,
it is more powerful to analyse them with unrelated controls
than by using transmissions within their families, so a solution
might be to identify previously genotyped controls from a
matching population and discard the transmission informa-
tion in the family. Using a statistical test that can incorporate
principal components to control for population stratification
and admixture, like SKAT, would provide a potential solution.
Of course, any study could be improved in this way by adding
repository control genotypes, so a more considered view is
that the reduced power of such families could be alleviated by
combining their transmission data, via pseudo-controls, with
repository control genotypes.
We have just touched upon an important point. Family-
based statistics, such as those presented here and elsewhere
(Lake et al., 2000), have an important property due to using
transmission rates. The transmission rate is independent of the
underlying allele frequency. The transmission from a parent
to a child is also independent of all other transmissions. Thus,
family-based statistics control for population stratification and
admixture inherently in the information they utilise for their
statistics. We have demonstrated above that population stratifi-
cation does not inflate type I errors, at least in these scenarios.
The tests aggregate across multiple rare SNPs and combining
SNPs with different allele frequencies from different popula-
tion strata may give an alterative to family- and transmission-
based tests to control for population stratification.
The genotypes of related individuals are not independent
therefore those case–control studies that contain related in-
dividuals have to contend with nonindependent data as well.
These problems are manageable in the case–control setting.
As mentioned above, using principle component analysis can
control for population stratification and clustering algorithms
remove any independence issues when applying case–control
statistics to multiple affected individuals in a family.
In conclusion, the use of enriched families is recommended
for detecting rare variant disease association, provided this
is within a case–control rather than a family-based design.
Selecting unrelated rather than family-based controls greatly
increases the power of statistical tests and their sensitivity to
variants with smaller effect sizes. When cases are not selected
for a family history, we found no advantage to using family-
based designs compared to case–control studies and the usual
concerns of population stratification (Mathieson & McVean,
2012) may be able to be alleviated due to the aggregate nature
of the tests. With little prior knowledge of the abundance of
causal and protective variants in a pool the SSU group of
statistical tests, which includes C-alpha and SKAT, offer the
most reliable and informative tests to use for analysis.
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Supporting Information
Additional Supporting Information may be found in the on-
line version of this article:
Table S1 List of statistical tests. Notes: 1. Not used for ASP as
type I error too high. 2. New family-based tests. 3. Clustering
for ASP. 4. No family test available.
Table S2 Parameters for population simulation. The most
scenarios use the baseline parameters of four causal SNPs and
six noncausal all with 0.5% MAF and OR based on the family
data. For the stratified tests two equally sized populations with
varying MAF, OR and baseline prevalence are used.
Table S3 The false positive (type I) error rates (in %) on
a stratified population for all statistical tests for each family
structure (trios, ASPs and enriched trios). Within
each family structure there are 24 statistical tests over the three
data formats (family, PCC and UCC). Those in bold indicate
an error rate of over 5.5%.
Table S4All power results (in %) for the stratified populations.
The optimal results for three family structures are given in
bold and dashes represent tests that failed to maintain a low
type I error or are not applicable for that data set. The results
are grouped according to correlations between statistical tests,
see main text for further details.
Figure S1 The results for three scenarios: varying OR for a
single causal variant, increasing the noise (noncausal variants)
and the sample size. (A) For one causal variant we vary its
OR from 1 to 3. (B) The total number of variants in these
scenarios rises from 10 to 50 with four causal in each case.
(C) These scenarios demonstrate the effect of changing the
sample size, from 100 to 1200 cases.
Figure S2 The OR required to give approximately 90%
power for the optimal test with increasing number of causal
variants out of 10. We see greater sensitivity for enriched trio
data (red) than either trio data (blue) or ASP data (green).
Figure S3 A flowchart of analysis for each scenario. We first
select the inputs: pedigree structure, number of families, num-
ber of variants, MAF profile (MAF for each variants) and OR
profile (OR for each variants). Then we repeat this process
1000 times to generate 1000 P-values for each statistical test.
The proportion below α = 0.05 gives the power for each
combination of data, format and test.
Figure S4 The results for the first three sets of scenarios
split by correlated group. Each panel consists of three sets of
graph, the left being increasing number of causal variants, the
middle being increasing OR with 1 causal variant and the
right being increasing OR with four causal variants. Each
column of panels relates to a data format: trios, ASPs and
enriched trios. We see strong correlation in each panel and
the increase in power experienced by UCC data in the second
and third columns.
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